Ken Griffin Adc Therapeutics Sa Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Citadel Advisors LLC holds 27,600 shares of ADCT stock, worth $87,216. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,600

Previous 1,700 1523.53%

Holding current value

$87,216

Previous $2,000 6050.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.66 - $5.29 $1.5 Million - $4.77 Million	-900,948 Reduced 48.61%	952,464 $4.28 Million
Q4 2023 Feb 14, 2024	SELL	$0.47 - $1.79 $491,013 - $1.87 Million	-1,044,709 Reduced 36.05%	1,853,412 $3.08 Million
Q3 2023 Nov 14, 2023	SELL	$0.72 - $2.37 $195,644 - $643,995	-271,728 Reduced 8.57%	2,898,121 $2.61 Million
Q2 2023 Aug 14, 2023	SELL	$1.9 - $2.66 $374,024 - $523,634	-196,855 Reduced 5.85%	3,169,849 $6.82 Million
Q1 2023 May 15, 2023	BUY	$1.92 - $5.45 $2.65 Million - $7.51 Million	1,378,836 Added 69.36%	3,366,704 $6.57 Million

Q4 2022 Feb 14, 2023	BUY	$2.87 - $5.24 $5.59 Million - $10.2 Million	1,948,077 Added 4895.77%	1,987,868 $7.63 Million
Q3 2022 Nov 14, 2022	BUY	$4.66 - $10.31 $185,426 - $410,245	39,791 New	39,791 $192,000
Q3 2021 Nov 15, 2021	SELL	$20.45 - $30.0 $95,153 - $139,590	-4,653 Reduced 19.39%	19,346 $525,000
Q2 2021 Aug 16, 2021	BUY	$20.38 - $27.04 $180,098 - $238,952	8,837 Added 58.28%	23,999 $584,000
Q1 2021 May 17, 2021	SELL	$22.75 - $34.05 $1.59 Million - $2.37 Million	-69,736 Reduced 82.14%	15,162 $370,000
Q4 2020 Feb 16, 2021	BUY	$25.26 - $38.02 $2.14 Million - $3.23 Million	84,898 New	84,898 $2.72 Million
Q3 2020 Nov 16, 2020	SELL	$32.87 - $51.05 $977,488 - $1.52 Million	-29,738 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.65 - $46.81 $881,731 - $1.39 Million	29,738 New	29,738 $1.39 Million

Others Institutions Holding ADCT

# of Institutions

Shares Held

36M

Call Options Held

156K

Put Options Held

55.9K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $245M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account